AnaCardio closes €62.5M Series B for heart-failure therapy Phase 3 advancement
AnaCardio, a clinical-stage biotech, raised €62.5M in Series B funding co-led by Novo Holdings and Ljungström family office to progress a novel heart-failure candidate toward Phase 3 trials. The round includes participation from existing and new institutional investors.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
AnaCardio announced completion of €62.5M Series B financing on 30 September 2026. Co-leads: Novo Holdings and Ljungström family office. Participants: Helsinn (originator), Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB (existing), and Innovestor Life Science (new).
Why it matters
Series B capital validates clinical-stage heart-failure program and de-risks progression to Phase 3, a pivotal inflection point in drug development. Novo Holdings' participation signals institutional confidence; syndicate breadth suggests strong conviction. Successful Phase 3 readiness could unlock partnership or acquisition optionality in a large therapeutic area.
Market transmission
Capital extends runway and reduces dilution risk for equity holders. Phase 3 advancement increases probability of regulatory approval and commercialization, improving enterprise value. Success could attract pharma licensing/acquisition interest, creating exit pathways for investors and employees.
What to watch
Phase 3 initiation timing and enrollment pace; interim efficacy/safety data; regulatory feedback; potential partnerships or M&A interest from larger pharma; follow-on financing needs and burn rate.
Sources:GlobeNewswire FranceGlobeNewswire France
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.